Sabin Vaccine Institute
Sabin Vaccine Institute is a Washington, D.C.-based non-profit that develops investigational filovirus vaccines (cAd3-Marburg and cAd3-Sudan Ebolavirus) and operates global immunization, vaccine acceptance, and HPV elimination programs for low- and middle-income countries, funded primarily by BARDA contracts and philanthropic grants.
- Company typePrivate
- Founded1993
- HeadquartersWashington, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Sabin Vaccine Institute does
Sabin Vaccine Institute is a Washington, D.C.-based 501(c)(3) non-profit organization founded in the early-to-mid 1990s and named in honor of Dr. Albert B. Sabin, developer of the oral polio vaccine. The institute operates with 51–100 employees across a portfolio spanning vaccine research and development, global immunization program delivery, vaccine acceptance research, and policy advocacy. Its core R&D focus is on filovirus vaccines, specifically the cAd3-Marburg and cAd3-Sudan Ebolavirus vaccine candidates built on the chimpanzee adenovirus type 3 (cAd3) viral vector platform originally developed by NIAID's Vaccine Research Center and Okairos, licensed from GSK in 2019. Both candidates are currently in Phase 2 clinical trials, with Phase 2 enrollment completed in March 2026.
Sabin's business model is non-commercial: rather than selling a product, it secures milestone-based, multi-year government contracts and philanthropic grants to fund R&D, training, and advocacy. BARDA is the largest single funder, having provided more than $250M cumulatively as of January 2025 across the Marburg and Sudan ebolavirus programs, including a contract worth up to $428M in total potential value. Other key funders include CEPI, the Wellcome Trust, the Bill & Melinda Gates Foundation, Gavi, UNICEF, UNITAID, and the World Bank's Global Financing Facility. Beyond R&D, Sabin operates a portfolio of community and research programs including the Global HPV Consortium (cervical cancer elimination), the Vaccination Acceptance Research Network (VARN, 800+ members across 27 countries), the Boost Community for frontline immunization professionals, the Coalition against Typhoid (CaT), the Influenzer Initiative, and applied epidemiology training programs. The institute's distribution is partner-mediated: vaccines in its pipeline are deployed during outbreak response (Rwanda 2024, Ethiopia 2025) directly to ministries of health, while training, evidence, and advocacy products scale through WHO (HQ, AFRO, EMRO), PAHO, UNICEF, Gavi, Africa CDC, FIGO, and OAFLAD.
The institute's primary beneficiaries are low- and middle-income countries targeted for HPV vaccine introduction, typhoid control, and routine immunization strengthening, as well as immunization professionals and frontline health workers in those settings. Sabin's customer base in funder terms is concentrated in U.S. government sources (BARDA) but geographically diversified in beneficiary terms, with active programs spanning the Americas, Sub-Saharan Africa, and South Asia, and a 139-country FIGO partnership footprint for HPV advocacy.
Sabin Vaccine Institute firmographics
Firmographics- Name
- Sabin Vaccine Institute
- Legal name
- The Albert B. Sabin Vaccine Institute, Inc.
- Website
- https://sabin.org
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Sabin Vaccine Institute is a Washington, D.C.-based non-profit that develops investigational filovirus vaccines (cAd3-Marburg and cAd3-Sudan Ebolavirus) and operates global immunization, vaccine acceptance, and HPV elimination programs for low- and middle-income countries, funded primarily by BARDA contracts and philanthropic grants.
- Ownership category
- akta.pro rank
Sabin Vaccine Institute industry classification
Industry- Product category
- Vaccine Research and Global Immunization Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Immunization & Vaccine Delivery Programs (BPADAIAB)
Keywords
Where Sabin Vaccine Institute is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sabin Vaccine Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Multi-year government contracts (BARDA): Long-horizon, milestone-based contracts with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for Marburg and Sudan Ebolavirus vaccine development; cumulative BARDA funding exceeded $250M as of January 2025, including a $214M Sudan Ebola contract with options up to $428M.
- Philanthropic grants (CEPI): Grant funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance COVID-19 vaccine development via the cAd3 platform.
- Philanthropic donations and grants (Wellcome Trust, Gates Foundation, Ready2Respond): Restricted and unrestricted contributions from philanthropic foundations and consortia (Wellcome Trust, Bill & Melinda Gates Foundation, Ready2Respond, Global Funders Consortium for Universal Influenza Vaccine Development) that fund clinical trials, fellowships, and advocacy programs.
- Program grants from multilateral agencies (UNICEF, Gavi, UNITAID, World Bank GFF): Project-based funding and co-financing from multilateral partners supporting immunization strengthening, HPV vaccination, and typhoid control in low- and middle-income countries.
Go-to-market motion4 records
Distribution channels3 records
Marketing channels8 records
Sabin Vaccine Institute product offering
Product offeringCore offering
Sabin Vaccine Institute develops investigational vaccines for filovirus outbreaks (Marburg and Sudan Ebolavirus) using the cAd3 viral vector platform licensed from GSK, currently in Phase 2 clinical trials. It also operates community-based global immunization programs and advocacy platforms, including the Boost Community, the Vaccination Acceptance Research Network (VARN), the Coalition against Typhoid, the Global HPV Consortium, and the Applied Epidemiology Program, focused on strengthening routine immunization in low- and middle-income countries.
Product overview
Sabin Vaccine Institute operates a portfolio of vaccine research, global immunization, and advocacy programs organized around four core impact areas: Generating Evidence, Exploring Vaccine Acceptance, Strengthening Immunization Capacity, and Powering Vaccine R&D. Its investigational vaccine products are the cAd3-Marburg Vaccine and cAd3-Sudan Ebolavirus Vaccine, both based on GSK's proprietary chimpanzee-adenovirus type 3 (cAd3) platform and currently in Phase 2 clinical trials funded by multi-year BARDA contracts. Complementing the R&D portfolio are community-based programs including the Boost Community platform, the Coalition against Typhoid (CaT), the Global HPV Consortium (with Sabin as secretariat), the Vaccination Acceptance Research Network (VARN), and the Applied Epidemiology Program. Additional content and convening products include the Influenzer Initiative, the "Getting to Zero" interview series, the COVID-19 Recovery for Routine Immunization Programs Fellowship, the annual Sabin Awards, and surveillance studies such as the Surveillance for Enteric Fever in Asia Project. Together, these offerings form an integrated platform combining vaccine development, evidence generation, community engagement, and global advocacy to extend vaccine access and innovation.
Differentiator
Problem solved
Functional benefit
Brands
- Global HPV Consortium: A collective of global partners seeking to accelerate the global effort to eliminate cervical cancer by 2030, operating across the three pillars of vaccination, screening, and early treatment. Sabin serves as secretariat for the Consortium.
- Coalition against Typhoid (CaT)
- Boost Community
- Vaccination Acceptance Research Network (VARN)
- Influenzer Initiative
- Sabin Awards
Products and services
- cAd3-Marburg Vaccine Investigational chimpanzee adenovirus type 3 (cAd3) vaccine candidate developed by Sabin to protect against Marburg virus disease, a filovirus with historical fatality rates of 24-88%. Currently in Phase 2 clinical trials, supported by BARDA contracts ($250M+ cumulative as of January 2025). Deployed for outbreak response in Rwanda (2024) and Ethiopia (2025, 640+ doses).
- cAd3-Sudan Ebolavirus Vaccine Investigational chimpanzee adenovirus type 3 (cAd3) vaccine candidate developed by Sabin to protect against Sudan ebolavirus disease, a filovirus with historical fatality rates of 41-100%. Currently in Phase 2 clinical trials, funded under multi-year BARDA contracts. Sabin did not pursue a separate Ebola Zaire vaccine since an approved product already exists.
- Boost Community Online community and storytelling initiative (Bright Spots) developed with immunization professionals to provide resources, connections, and trainings for those working in challenging immunization contexts, especially in low- and middle-income countries.
- Coalition against Typhoid (CaT) Global forum housed at Sabin connecting researchers, advocates, practitioners, and policy-makers to elevate typhoid, paratyphoid, and invasive nontyphoidal Salmonella (iNTS) disease as global health priorities; includes the biennial International Conference on Typhoid & Other Invasive Salmonelloses.
- Global HPV Consortium Transdisciplinary movement launched in September 2023 to prevent HPV infection and eliminate cervical cancer as a public health concern by operating across vaccination, screening, and early treatment. Sabin serves as secretariat for the consortium.
- Vaccination Acceptance Research Network (VARN) Network of more than 800 multidisciplinary stakeholders from academic research, NGOs, and the policy, public health, and private sectors exploring factors that drive vaccine acceptance, demand, and vaccination uptake in low- and middle-income countries. Sabin provides global leadership in applying social and behavioral science insights.
- Applied Epidemiology Program Sabin's Applied Epidemiology program generates data-driven evidence on infectious disease spread, vaccine safety, immunogenicity, effectiveness, and impact to inform vaccine policy and decision-making; supports typhoid serosurveillance and country case studies in LMICs.
- Influenzer Initiative (Influenza Vaccine Innovation Program) Sabin's influenza-focused program aimed at catalyzing collaboration to accelerate innovation in a universal influenza vaccine capable of protecting against all strains of the disease; includes the IVI program and the "Influence of the Stars" documentary.
- COVID-19 Recovery for Routine Immunization Programs Fellowship Fellowship launched with WHO in May 2022 to rebuild routine immunization disrupted by COVID-19, strengthening capacity of national and sub-national immunization staff as part of WHO's 'Big Catch-Up' initiative.
- Surveillance for Enteric Fever in Asia Project (SEAP) Multi-phase surveillance project (Phases I-III) monitoring the burden of enteric fever (typhoid and paratyphoid) in Bangladesh, Nepal, and Pakistan, including changes during the COVID-19 pandemic; data informed WHO's 2018 revised position paper on typhoid vaccination.
Quantifiable outcome
- $250M+ cumulative BARDA funding as of January 2025 for Marburg and Sudan Ebolavirus vaccine development
- +7 more outcomes
Companies that use Sabin Vaccine Institute
Customer profileSegments6 records
Ideal customer profiles4 records
Sabin Vaccine Institute technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Sabin Vaccine Institute partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered flagship, core and minor.
- GSKflagshipGSK is the original owner/licensor of the cAd3 (chimpanzee adenovirus type 3) viral vector platform that Sabin uses to develop its Marburg and Sudan Ebolavirus vaccine candidates. The platform rights were licensed/acquired by Sabin and underpin its entire filovirus vaccine portfolio.
- World Health Organization (WHO)coreWHO collaborates with Sabin on vaccine R&D priorities and is referenced as a key global partner for the institute's filovirus and broader immunization programs.
- WHO Regional Office for Africa (WHO AFRO)coreWHO Africa leadership (Dr. Matshidiso Moeti) is featured in Sabin's HPV content as a key partner for advancing HPV vaccine introduction and immunization across African countries.
- PAHO (Pan American Health Organization)corePAHO Director Dr. Jarbas Barbosa is featured in Sabin's HPV content; PAHO supports HPV vaccine introduction in the Americas, where 48 of 51 countries have introduced the HPV vaccine.
- WHO Regional Office for the Eastern Mediterranean (WHO EMRO)coreWHO EMRO is a regional partner supporting Sabin's immunization and country case study work (e.g., Nepal) on vaccine-preventable disease surveillance.
- Africa CDCcoreAfrica CDC is a strategic partner supporting Sabin's HPV vaccination and broader immunization initiatives across African Union member states, including Nigeria.
- FIGO (International Federation of Gynecology and Obstetrics)flagshipFIGO is a flagship partner for Sabin's HPV vaccine work, with a national society footprint spanning 139 countries, supporting physician advocacy and HPV vaccine introduction.
- Organization of African First Ladies for Development (OAFLAD)flagshipSabin has a formal agreement with OAFLAD to advance immunization and HPV vaccination across Africa, leveraging the advocacy platform of African First Ladies.
- TogetHER for HealthcoreTogetHER for Health is a partner in Sabin's HPV-related resources and advocacy work, focused on cervical cancer elimination and HPV vaccine access in LMICs.
- KEMRI (Kenya Medical Research Institute)coreKEMRI is referenced as a research partner in Sabin's HPV work in Kenya and is associated with mobile-clinic screening programs reaching tens of thousands of women.
- VillageReachcoreVillageReach is a partner in Sabin's applied epidemiology and immunization delivery work, with jointly authored technical papers on vaccine logistics and zero-dose children.
- Aspen Institute (Sabin–Aspen Vaccine Science and Policy Group)coreSabin co-convenes the Vaccine Science and Policy Group with the Aspen Institute, bringing together senior leaders across science, industry, and policy to discuss vaccine innovation and equity.
- CIDRAP (Center for Infectious Disease Research and Policy)coreCIDRAP is a content partner with Sabin on the Getting to Zero podcast series covering vaccine and infectious disease topics.
- Stop TB PartnershipminorStop TB Partnership is referenced as a collaborator in Sabin's immunization capacity-strengthening work alongside other global health partners.
- Pandemic Action NetworkminorPandemic Action Network is referenced as a partner in Sabin's broader pandemic preparedness and vaccine advocacy ecosystem.
- Ready2RespondminorReady2Respond is referenced as a partner/funding coalition in Sabin's outbreak response and immunization programs (e.g., Nursing Challenge).
- UNICEFcoreUNICEF is a strategic partner supporting Sabin's immunization and vaccine delivery programs for children in LMICs.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
Sabin Vaccine Institute competitors and assessment
Company assessmentDirect peers
- International Vaccine Institute (IVI): Non-profit international organization dedicated to vaccine research and development for global health. Most directly comparable peer in mission, scope, and grant-funded operating model.
- PATH: International non-profit global health organization focused on vaccine development and access in LMICs. Similar operating model with funding from government and philanthropic sources.
- Center for Vaccine Development at Texas Children's Hospital: Academic non-profit research center developing vaccines for global health. Similar mission and operating model; develops vaccines for neglected diseases including those affecting LMICs.
- Access to Advanced Health Institute (AAHI, formerly IDRI): Non-profit biotech developing vaccines and immune therapies for global health. Similar focus and comparable operational scale to Sabin.
- Bharat Biotech: Major Indian vaccine manufacturer with rotavirus and other vaccines. Commercial peer developing vaccines for similar disease areas, particularly rotavirus, at greater scale.
- Serum Institute of India: World's largest vaccine manufacturer by doses. Operates in similar disease areas including rotavirus, polio, and rubella. Commercial peer at significantly larger scale than Sabin.
Broad incumbents
- Coalition for Epidemic Preparedness Innovations (CEPI): Larger non-profit funding vaccine R&D for epidemic threats. Sabin received $6.3M from CEPI for dose-optimizing trial. Strong partnership and partially overlapping mission.
- Gavi, the Vaccine Alliance: Public-private partnership that funds vaccine access in LMICs. Listed as Sabin's partner; operates at larger scale with similar mission of expanding vaccine access globally.
- World Health Organization (WHO): UN agency setting global vaccine policy and convening. Sabin partners with WHO regional offices; both organizations are central to the global vaccine policy and access ecosystem.
Others
- Bill & Melinda Gates Foundation: Major philanthropic funder of global health initiatives including vaccine R&D. Listed as a Sabin partner; the foundation funds multiple global health non-profits and convenes the global vaccine ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Sabin Vaccine Institute social profiles
Digital presenceSabin Vaccine Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sabin Vaccine Institute leadership team
Management profileNumber of profiles
Profiles3 records
Sabin Vaccine Institute funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sabin Vaccine Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sabin Vaccine Institute
What does Sabin Vaccine Institute do?
Sabin Vaccine Institute develops investigational vaccines for filovirus outbreaks (Marburg and Sudan Ebolavirus) using the cAd3 viral vector platform licensed from GSK, currently in Phase 2 clinical trials. It also operates community-based global immunization programs and advocacy platforms, including the Boost Community, the Vaccination Acceptance Research Network (VARN), the Coalition against Typhoid, the Global HPV Consortium, and the Applied Epidemiology Program, focused on strengthening routine immunization in low- and middle-income countries.
Is Sabin Vaccine Institute a public or private company?
Sabin Vaccine Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Sabin Vaccine Institute founded?
Sabin Vaccine Institute was founded in 1993. It employs 51 to 100 people.
Where is Sabin Vaccine Institute based?
Sabin Vaccine Institute is headquartered in Washington, United States, in the North America region.
How does Sabin Vaccine Institute make money?
Four revenue lines are on record. Multi-year government contracts (BARDA) is the primary driver. The others are philanthropic grants (CEPI), philanthropic donations and grants (Wellcome Trust, Gates Foundation, Ready2Respond) and program grants from multilateral agencies (UNICEF, Gavi, UNITAID, World Bank GFF).
Who are Sabin Vaccine Institute's main competitors?
Direct peers on record are International Vaccine Institute (IVI), PATH, Center for Vaccine Development at Texas Children's Hospital, Access to Advanced Health Institute (AAHI, formerly IDRI), Bharat Biotech and Serum Institute of India. Broad incumbents are Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and World Health Organization (WHO). Bill & Melinda Gates Foundation is listed as an others.
Does Sabin Vaccine Institute have an API?
No public API is recorded for Sabin Vaccine Institute.
What industry is Sabin Vaccine Institute in?
Sabin Vaccine Institute's product category is Vaccine Research and Global Immunization Services. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 541714 and its SIC code is 2836.